Latest news with #IPF
United News of India
3 days ago
- Business
- United News of India
Gita Gopinath set to leave IMF, will join Harvard economics faculty
New Delhi, July 22 (UNI) Gita Gopinath, First Deputy Managing Director (FDMD) at the IMF, will leave the organization at the end of August and rejoin Harvard University as the inaugural Gregory and Ania Coffey Professor of Economics. This announcement was made by Kristalina Georgieva, Managing Director of the International Monetary Fund (IMF). The International Monetary Fund is a global institution and specialized agency of the United Nations. It is headquartered in Washington D.C. Gita Gopinath joined the IMF in January 2019 and rose to the post of deputy managing director of the Fund in 2022. In her post on X, she said, 'I will now return to my roots in academia where I look to push the research journey in the domain of international finance and macroeconomics to tackle the ongoing economic challenges.' In making the announcement of Gita's departure from the IMF, MD Kristalina applauded her and highlighted her leadership qualities and commitment to the members and mission of the International Monetary Fund. Kristalina said, 'The analytical rigor of Gita Gopinath in framing the policies of international finance is extraordinary. Gita also played an instrumental role in monitoring the country's surveillance and Fund country programs, especially for Argentina and Ukraine,' she added Gita Gopinath was the first female Chief Economist in the history of the IMF. She has a rare combination of brilliance and humility. In her tenure of five years at the IMF, Gita led some initiatives, including the expansion of the Fund's work on the IPF or Integrated Policy Framework program. Gita also co-authored the Pandemic plan on how to deal with the COVID-19 crisis. After Gita stepped down from the IMF, there were multiple challenges across the fund amid economic uncertainties. The successor of Gopinath is yet to be announced. UNI SAS PRS
Al Etihad
4 days ago
- Business
- Al Etihad
Gita Gopinath to leave IMF, to rejoin Harvard economics faculty
21 July 2025 22:41 WASHINGTON (ALETIHAD)International Monetary Fund (IMF) Managing Director Kristalina Georgieva announced on Monday that Gita Gopinath, the Fund's First Deputy Managing Director (FDMD), will step down at the end of August to return to Harvard will take up the position of inaugural Gregory and Ania Coffey Professor of Economics in the Department of joined the IMF in January 2019 as Chief Economist and was appointed FDMD in January a media statement, Georgieva praised Gopinath as 'an outstanding colleague—an exceptional intellectual leader, dedicated to the mission and members of the Fund, and a fabulous manager, always showing genuine care for the professional standing and wellbeing of our staff.'She continued: 'She came to the Fund as a highly respected academic in macroeconomics and international finance. Admiration for Gita only grew through her time at the Fund, where her analytical rigour was paired with practical policy advice to the membership during an especially challenging period, which included the pandemic, wars, the cost-of-living crisis, and major shifts in the global trading system.'Georgieva also highlighted Gopinath's leadership on policy and surveillance: 'Gita steered the Fund's analytical and policy work with clarity, striving for the highest standards of rigorous analysis at a complex time of high uncertainty and a rapidly changing global economic environment. She oversaw the Fund's multilateral surveillance and analytical work on fiscal and monetary policy, debt, and international trade.'She noted that Gopinath played a key role in country programmes, including for Argentina and Ukraine, and regularly represented the Fund at major international platforms, including the G-7 and G-20.'She has a rare combination of brilliance and humility, which we have all come to admire,' Georgieva added.'As Chief Economist, Gita ensured that the World Economic Outlook remained the preeminent report on the global economy—an especially impressive achievement during the COVID-19 pandemic.''She also spearheaded the Fund's work on the Integrated Policy Framework (IPF), which helps countries develop policies for macroeconomic and financial stability. Gita co-authored the Pandemic Plan on how to end the COVID-19 crisis—an intellectual contribution widely hailed for setting global vaccination targets at a feasible cost.'Commenting on her departure, Gopinath said: 'I am truly grateful for my time at the IMF, first as Chief Economist and then as First Deputy Managing Director. I have had the privilege of working closely with the IMF's brilliant and committed staff, colleagues in management, the Executive Board, and country authorities.'She added: 'I am especially thankful to Kristalina and her predecessor, Christine Lagarde, for the once-in-a-lifetime opportunity to serve the IMF's membership during a period of unprecedented challenges.' 'I now return to my roots in academia, where I look forward to continuing to push the research frontier in international finance and macroeconomics to address global challenges, and to training the next generation of economists.' Source: Aletihad - Abu Dhabi
The Hindu
5 days ago
- Entertainment
- The Hindu
Chandra Barot, director of Amitabh Bachchan's iconic film ‘Don,' passes away at 86
Veteran filmmaker Chandra Barot, best known for helming Amitabh Bachchan's 1978 cult classic Don, passed away at a hospital in Mumbai on Sunday (July 20). He was 86. Chandra was battling 'Idiopathic Pulmonary Fibrosis' (IPF-fibrosis of lungs) for the past 11 years and had been receiving treatment at the Guru Nanak Hospital, as per his family. 'Chandra passed away at the Guru Nanak Hospital this morning at 6.30 due to cardiac arrest caused by a chest infection. He had IPF, which is fibrosis of the lungs, for the past 11 years,' his wife, Deepa Barot told PTI. Farhan Akhtar, who is directing the third film in the renewed Don franchise, paid tribute to Chandra on Instagram, writing, 'Saddened to learn that the director of the OG Don is no more. RIP Chandra Barot-ji. Deepest condolences to the family.' Born and raised in Tanzania, Chandra worked at the Barclays Bank in Dara-es-Salam, before racial turmoil forced him to leave the country in 1967. In India, he pursued his passion in filmmaking and joined late veteran actor-director Manoj Kumar as an assistant director, working in films such as Purab Aur Pachhim, Yaadgaar, Shor andRoti Kapada Aur Makaan. In 1978, he made a film he would forever be remembered for: the Amitabh Bachchan-starrer, Don, which had a script written by Salim–Javed. However, pundits would fondly remember him for the reason he directed the film in the first place. Chandra wanted to help his friend, cinematographer-producer Nariman Irani, who had suffered terrible financial losses reportedly due to the failure of 1972's Zindagi Zindagi. After Don, Chandra helmed the Bengali film Aashrita in 1989, and returned to Hindi cinema with 1991's Pyar Bhara Dil. Chandra's subsequent projects, Hong Kong Wali Script and Neil Ko never saw the light of the day. However, Don lived on. In 2006, the film was rebooted in a new franchise by director Farhan Akhtar and lead star Shah Rukh Khan. They reunited again for a sequel, the 2011's Don 2: The King Is Back. Farhan is now making a third Don film with actor Ranveer Singh in the lead. The legacy of Don stretches far and beyond Bollywood, paving way for renditions headlined by the likes of Rajinikanth, Ajith Kumar, Prabhas and Mohanlal. Chandra Barot is survived by his wife and a son. The news about Chandra's death has shocked the film industry. Fans, well-wishers and colleagues from the film fraternity have been expressing their condolences. (with inputs from PTI)
Yahoo
18-07-2025
- Business
- Yahoo
This ‘Strong Buy' Stock Could Be the Next Big Biotech Breakout
Clinical-stage biotech stocks carry significant risks, but also offer explosive upside potential. These companies are built around early stage innovations that, if successful, can evolve into billion-dollar therapies or entire treatment platforms. The company's valuation at this stage is less dependent on fundamentals like revenue or profit and instead hinges on scientific milestones, meaning a single clinical trial result or regulatory approval can send the stock soaring. Valued at $212 million, Tvardi Therapeutics (TVRD) is a clinical-stage biopharmaceutical company developing oral small-molecule drugs targeting STAT3, a protein linked to fibrosis and certain cancers when overactive. Following its merger with Cara Therapeutics, Tvardi has rapidly gained traction in the biotech space. More News from Barchart Insider Trading Alert: Here's Who Bought Nvidia and AMD Stock Before the U.S. Chip Deal with China Dear Tesla Stock Fans, Mark Your Calendars for July 23 Robinhood Keeps Hitting New Highs. How Should You Play HOOD Stock Here? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. The stock is already up 32% in the year to date, and analysts believe it still has substantial room to run. Setting the Stage for a Strong Pipeline The company's lead candidate, TTI-101, is an oral pill that is designed to block overactive STAT3. It is currently in Phase 2 trials for Idiopathic Pulmonary Fibrosis (IPF), a serious lung-scarring disease, and Hepatocellular Carcinoma (HCC), a type of liver cancer. The REVERT IPF Phase 2 trial is evaluating the efficacy of TTI-101 alone and in combination with the approved drug nintedanib to treat patients with IPF, a progressive and often fatal lung disease with few treatment options. The company completed enrollment for the Phase 2 trial at the end of May and expects top-line data by the fourth quarter of this year. Success in this trial would validate oral STAT3 as a therapeutic mechanism and provide momentum for additional indications such as HCC. What's noteworthy is that the U.S. Food and Drug Administration (FDA) has designated TTI-101 as an orphan drug in both IPF and HCC. This designation is given to drugs that treat rare diseases with significant unmet needs. The FDA has also granted TTI-101 Fast Track Designation for HCC only. This will speed up the candidate's review process. Tvardi also expects top-line data from its REVERT Liver Cancer Phase 1b/2 clinical trial for HCC in the first half of 2026. Additionally, Tvardi has TTI‑109, a next-generation STAT3 inhibitor, in the preclinical stage, which means it has not yet entered human trials. This suggests that it could enter clinical development within 12 months. If pursued, it would broaden Tvardi's fibrosis-related disease portfolio and strengthen its long-term clinical pipeline. The company's products are still in the clinical stage and have not yet been approved for the market. As a result, it generates no revenue and requires external financing to run its operations. The merger with Cara was critical not only for securing a path to a Nasdaq listing, but also for strengthening its financing. With approximately $28.3 million in private placement funding and $23.8 million in net cash from Cara, Tvardi has secured a cash runway until late 2026, covering the critical readout periods of its lead candidate's trials. Tvardi Therapeutics stock represents a typical high-risk, high-reward biotech investment. With no revenue, its valuation is entirely dependent on clinical trial results. The company has breakout potential, which is why Wall Street is optimistic. Tvardi's breakthrough IPF results may spark major collaborations. Furthermore, positive HCC outcomes would broaden its oncology portfolio. On the flip side, risks include clinical trial or safety failures, as well as delays in regulatory approvals. This is why the stock is appropriate for investors who are comfortable with the volatility that comes with clinical-stage biotech stocks. What Does Wall Street Say About Tvardi's Stock? Overall, Wall Street rates the stock a 'Strong Buy.' Of the six analysts covering TVRD stock, five of them rate it as a 'Strong Buy,' with one suggesting a 'Moderate Buy.' The average price target is $58.33, which represents 151% upside from current levels. Its high target price of $78 implies the stock can surge 233% over the next 12 months. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
17-07-2025
- Business
- Time of India
Transactions will not affect Deccan facility: Sahyadri
Pune: The Sahyadri Group of Hospitals on Thursday released a press statement, claiming that the acquisition of its majority shares by Manipal Group would not impact the functioning of the facility in the Deccan area. Dr Amitkumar Khatu, the chief legal & compliance officer, Sahyadri Hospitals Group, said in the statement, "The ongoing transaction is a transfer of equity shares in Sahyadri Hospitals Private Limited, which manages multiple hospitals across Maharashtra. This is not the first time such a transaction has taken place. Each time, patient care and hospital operations continued seamlessly. Our legal obligations remain unchanged. " Of the eight hospitals run by the group, only one, the Deccan branch, operates under a charitable trust model, read the statement. The statement said the land on which Deccan Hospital operated was owned by the Pune Municipal Corporation (PMC) and was leased to the trust in 1998 under a 99-year agreement. You Can Also Check: Pune AQI | Weather in Pune | Bank Holidays in Pune | Public Holidays in Pune "This lease arrangement remains intact and has no bearing on the recent equity transaction. The land was leased to the trust upon payment of the entire lease premium at the then prevailing market rate and payment of the entire lease rent for 99 years," read the statement. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like An engineer reveals: One simple trick to get internet without a subscription Techno Mag Learn More Undo The hospital also claimed to have complied with the said agreement by offering free treatment to all patients referred by the civic body. "Over the past few years, this averaged around 260 bed days annually, and not a single referred case was ever denied. Eligible patients will keep getting IPF (indigent patients fund) benefits," the statement said. A spokesperson of the Manipal Group said, "The transaction between Manipal and Sahyadri would be concluded only after regulatory approvals. Therefore, while it is premature for Manipal to comment, we would like to convey that our intention is to continue with the existing participation in all schemes that are to provide treatment to poor patients." Taking cognisance of multiple allegations made against the transactions, the PMC's health department on Thursday sent a notice to the Konkan Mitra Mandal Medical Trust seeking explanations. Dr Suryankant Devkar, assistant health officer, PMC, said, "We received a letter from an advocate claiming that the recent transactions between Sahyadri Group of Hospitals and Manipal Group was an illegal commercial transfer. We have attached it with our notice and sought an explanation on all the issues raised by the said advocate." Advocate Sushrut Kamble had sent the letter to the chief medical officer. He said, "The lease to transfer land was originally meant for the charitable purpose of ensuring affordable healthcare to needy patients and not to earn profits like a corporate firm, but this is what is currently happening at this hospital."
